Aquestive Therapeutics, Inc.
AQSTNasdaqCIK 1398733HealthcareFiscal year ends Dec 31
Reports and events: 226 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-1920:04 ET | 8-K | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001398733-26-000063 |
| 2026-10-1511:21 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001398733-26-000058 |
| 2026-10-1411:21 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001398733-26-000056 |
| 2026-09-2911:22 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001398733-26-000052 |
| 2026-09-2511:59 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001398733-26-000048 |
| 2026-09-1711:02 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001398733-26-000044 |
| 2026-08-1120:10 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001398733-26-000042 |
| 2026-08-1120:06 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001398733-26-000041 |
| 2026-08-1011:05 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001398733-26-000035 |
| 2026-06-1020:02 ET | 8-K | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001398733-26-000033 |
| 2026-05-1320:08 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001398733-26-000030 |
| 2026-05-1320:04 ET | 8-K | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 2.02 Results of operations; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001398733-26-000029 |
| 2026-04-2421:00 ET | DEF 14A | Proxy statementPeriod 2026-06-10 | 0001140361-26-016757 |
| 2026-03-3011:44 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001398733-26-000022 |
| 2026-03-2011:36 ET | 8-K | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001398733-26-000020 |
| 2026-03-0421:21 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001398733-26-000018 |
| 2026-03-0421:10 ET | 8-K | 1.01 Entry into a material agreement; 2.02 Results of operations; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001398733-26-000016 |
| 2026-02-2613:07 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001398733-26-000007 |
| 2026-02-0212:03 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001398733-26-000005 |
| 2026-01-0912:18 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001398733-26-000003 |
| 2025-11-0621:01 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001398733-25-000030 |
| 2025-11-0521:07 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001398733-25-000028 |
| 2025-11-0521:04 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001398733-25-000027 |
| 2025-10-0811:23 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001398733-25-000022 |
| 2025-10-0112:41 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001398733-25-000020 |
| 2025-09-0812:32 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001398733-25-000018 |
| 2025-09-0411:11 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001398733-25-000016 |
| 2025-08-1501:37 ET | 8-K | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-25-031374 |
| 2025-08-1410:26 ET | 8-K | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-25-031008 |
| 2025-08-1120:11 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0001398733-25-000013 |
| 2025-08-1120:05 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001398733-25-000012 |
| 2025-07-1511:54 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-25-034890 |
| 2025-06-1611:48 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-25-031455 |
| 2025-06-1121:21 ET | 8-K | 5.07 Shareholder vote results | 0001628280-25-030804 |
| 2025-06-0220:03 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-25-028813 |
| 2025-05-1220:07 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0001628280-25-024664 |
| 2025-05-1220:05 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-25-024659 |
| 2025-04-2520:31 ET | DEF 14A | Proxy statementPeriod 2025-06-11 | 0001140361-25-015781 |
| 2025-04-0112:26 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-25-015759 |
| 2025-03-1012:10 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-25-011465 |
| 2025-03-0521:29 ET | 10-K | Annual reportPeriod 2024-12-31 | 0001628280-25-010506 |
| 2025-03-0521:13 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-25-010422 |
| 2025-02-1212:22 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-25-005018 |
| 2025-01-1312:07 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-25-001229 |
| 2024-12-1913:02 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-24-051956 |
| 2024-12-0213:08 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-24-049497 |
| 2024-11-0721:01 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001628280-24-046223 |
| 2024-11-0621:01 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-24-045687 |
| 2024-11-0421:42 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0001628280-24-045030 |
| 2024-11-0421:40 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-24-045028 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:12 ET. Listed shows no prices and gives no investment advice.